Related Experiment Video
Updated: Aug 20, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury
1Medical Molecular Biology Unit, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK. a.stephanou@ich.ucl.ac.uk
Abstract:
Ischaemia/reperfusion (I/R) injury results in the death of irreplaceable cardiac myocytes by a programme cell death or apoptosis. The signal transducers and activators of transcription (STAT) factors function as modulators of cytokine signaling and sensors responding to cellular stress. Interestingly, many studies have demonstrated that although they have a similar structural organization, STAT-1 and STAT-3 have apposing effects on processes such as differentiation or apoptosis. For example, STAT-1 has been shown to induced apoptosis, whilst STAT3 is able protect cardiac myocytes following ischaemia/reperfusion (I/R) injury. Many of the effects of STAT-1 and STAT-3 involve the direct binding to DNA and transcriptional activation of target genes. However, recent studies have shown that for STAT-1 some of its effects appear not to require DNA binding. For example, induction of apoptosis by STAT-1 can be produced by the C-terminal activation domain in the absence of the DNA binding domain. This therefore, appears to involve a co-activator effect in which STAT-1 is recruited to DNA via a DNA-bound transcription factor. In this regard, it is of interest that STAT-1 but not STAT-3 has been shown to interact with p53 and enhance its growth arrest and apoptosis- inducing properties. Hence, the finding that STAT-1 and STAT-3 can modulate the apoptotic programme both by direct DNA binding or via a co-activator mechanism and despite their very similar structures, suggests that these related factors may be therapeutic targets against the damage myocardium following I/R injury. Recently, we reported that the polyphenolic agent epigallocatechin-3-gallate (EGCG), a major constituent of green tea and a potent inhibitor of STAT-1 activation, protects the myocardium against I/R injury.
Insights
Epigallocatechin-3-gallate (EGCG) protects the heart from ischemia/reperfusion (I/R) injury by inhibiting STAT-1 activation. This finding offers a potential therapeutic strategy targeting signal transducers and activators of transcription (STAT) factors to prevent cardiac cell death.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Cell Death Mechanisms
Background:
- Ischaemia/reperfusion (I/R) injury leads to irreversible cardiac myocyte death via apoptosis.
- Signal transducers and activators of transcription (STAT) factors modulate cellular stress responses and cytokine signaling.
- STAT-1 and STAT-3 exhibit opposing roles in apoptosis, with STAT-1 inducing and STAT-3 protecting against I/R injury.
Purpose of the Study:
- To investigate the therapeutic potential of epigallocatechin-3-gallate (EGCG) in mitigating I/R injury.
- To explore the role of STAT-1 and STAT-3 in I/R-induced cardiac cell death.
- To elucidate the mechanisms by which STAT-1 influences apoptosis, including DNA-binding independent pathways.
Main Methods:
- Investigated the effects of STAT-1 and STAT-3 on cardiac myocyte apoptosis.
- Examined the interaction between STAT-1 and p53.
- Assessed the protective effects of EGCG on the myocardium against I/R injury.
Main Results:
- STAT-1 induces apoptosis, while STAT-3 offers protection in I/R injury models.
- STAT-1 can mediate apoptosis through a co-activator mechanism, interacting with p53.
- Epigallocatechin-3-gallate (EGCG) demonstrated significant cardioprotective effects against I/R injury by inhibiting STAT-1 activation.
Conclusions:
- STAT-1 and STAT-3 are critical modulators of cardiac apoptosis in I/R injury, acting through distinct mechanisms.
- Targeting STAT-1 activation presents a promising therapeutic avenue for myocardial protection.
- EGCG, a green tea constituent, shows potential as a therapeutic agent for I/R injury due to its STAT-1 inhibitory properties.
Related Concept Videos
The JAK-STAT Signaling Pathway
Ischemic Stroke ll: Pathophysiology
